(Q50731169)

18 March 2018

reason for preferred rank

title

Cost‐effectiveness and lung cancer clinical trials (English)

1 reference

14 March 2024

Cost-effectiveness and lung cancer clinical trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14508837

14 March 2024

1 reference

14 March 2024

author name string

Wei Du

1

1 reference

18 March 2018

Shirish Gadgeel

3

1 reference

18 March 2018

Judith Abrams

4

1 reference

18 March 2018

Jaxk H. Reeves

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14508837

14 March 2024

William P. Peters

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14508837

14 March 2024

language of work or name

English

0 references

publication date

1 October 2003

1 reference

18 March 2018

number of pages

6

1 reference

full work available at URL

inferred from page(s)

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.11659

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14508837

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.11659

14 March 2024

1 reference

https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.11659

14 March 2024

1 reference

14 March 2024

1 reference

18 March 2018

volume

98

1 reference

18 March 2018

issue

7

1 reference

18 March 2018

page(s)

1491-1496

1 reference

18 March 2018

Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11659

7 January 2021

Centralised treatment, entry to trials and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11659

7 January 2021

Assigning care costs associated with therapeutic oncology research: a modest proposal

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11659

7 January 2021

The crisis in clinical cancer research. Third-party insurance and investigational therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11659

7 January 2021

Clinical trials. Access and reimbursement

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11659

7 January 2021

A swift response to a "modest" proposal

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11659

7 January 2021

Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11659

7 January 2021

Accrual to cancer clinical trials: directions from the research literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11659

7 January 2021

Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11659

7 January 2021

Incremental costs of enrolling cancer patients in clinical trials: a population-based study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11659

7 January 2021

Clinical trials: are they a good buy?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11659

7 January 2021

Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11659

7 January 2021

Cost of care for patients in cancer clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11659

7 January 2021

Impact of clinical trials on the cost of cancer care

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11659

7 January 2021

Bootstrap Methods for Standard Errors, Confidence Intervals, and Other Measures of Statistical Accuracy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11659

7 January 2021

Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer

1

1 reference

14 March 2024

Identifiers

DOI

10.1002/CNCR.11659

1 reference

18 March 2018

1 reference

18 March 2018